

Pharmacy BULLETIN BOARD

Hospital Issue ■ Monday July 7, 2014

UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

| Product | Sizes | Odan Code | Kohl & Frisch Code | McKesson Code | McMahon Code |
|------------------------------------|--------|-----------|--------------------|---------------|--------------|
| UriSec® 10% Cream NPN 80005397 | 75 g | 38075 | 32617 | 513085 | 26638401 |
| | 120 g | 38045 | 32618 | 513341 | 26638301 |
| UriSec® 12% Lotion NPN 00514896 | 250 mL | 230J | 48909 | 115493 | 26623101 |
| UriSec® 22% Cream NPN 00396125 | 120 g | 220Q | 46312 | 115444 | 26623201 |
| | 225 g | 220C | - | 153486 | 26537801 |
| | 454 g | 220R | 46309 | 848549 | 26632301 |
| UriSec® 40 Cream NPN 80005531 | 15 g | 45014 | 114939 | 003743 | - |
| | 30 g | 45028 | 32606 | 799437 | 27127401 |
| | 100 g | 45067 | 32616 | 799494 | 26640001 |

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec® is a registered trademark of Odan Laboratories Ltd.

WATERLOO: Manulife has entered into a three year sponsorship as the Mental Health at Work® Champion of Excellence with Excellence Canada to help improve the mental health of Canadians within the workplace. Manulife will work with Excellence Canada to further promote and administer the program for organizations across Canada.

FROM THE NEWSWIRE

MISSISSAUGA: Women with HER2-positive metastatic breast cancer in Manitoba will now be able to access a new treatment option through CancerCare Manitoba. The Provincial Oncology Drug Program has approved the addition of KADCYLA® (trastuzumab emtansine) to the CancerCare Manitoba Drug Formulary. CancerCare Manitoba has approved KADCYLA as second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status equal to or less than two, who have received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or have disease recurrence during or within six months of completing adjuvant therapy with trastuzumab plus chemotherapy.

MONTREAL: Kids with Type 1 Diabetes (T1D) face many difficulties and challenges, including learning to self-inject. But now a new insulin pen from Sanofi Canada has been designed to help these youngsters through the process.

OTTAWA: The Government of Canada has language labelling regulations that will help improve the safe use of drugs by making drug labels and packaging information easier to read and understand, as promised in the 2013 Speech from the Throne. The Regulations Amending the Food and Drug Regulations (Labelling, Packaging and Brand Names of Drugs for Human Use) were published in Canada Gazette, Part II and are part of the Plain Language Labelling Initiative. The regulations will gradually be phased into effect, delivering key safeguards.

OAKVILLE, ON: As scientific evidence has accumulated, there has been a movement toward lower dose estrogen formulations of combined oral contraceptives, which demonstrate similar efficacy with fewer side effects than higher dose options. Actavis Specialty Pharmaceuticals Co. has announced the Health Canada approval and availability of LOLO™ (ethinyl estradiol and norethindrone acetate tablets), a new low-dose oral contraceptive indicated for the prevention of pregnancy that uses only 10 micrograms (mcg) of estrogen — the lowest dose of any combined oral contraceptive.